SAN DIEGO and VANCOUVER, British Columbia, March 29, 2017 /PRNewswire/ -- Sophiris Bio
Inc. (NASDAQ: SPHS) (the "Company" or "Sophiris"), a
clinical late-stage biopharmaceutical company developing topsalysin
(PRX302) for the treatment of patients with urological diseases,
today announced that Randall E. Woods, president and chief
executive officer, will present a corporate overview at the
16th Annual Needham Healthcare Conference. The
presentation is scheduled for Tuesday, April 5,
2017 at 3:40 p.m. EDT in New York, New York.
The presentation will be webcast live and can be accessed
through the Investor Relations page at www.sophirisbio.com. A
replay of the presentation will be available on the Company's
website for 90 days.
About Sophiris
Sophiris Bio Inc. is a
biopharmaceutical company developing topsalysin (PRX302) for the
treatment of patients with urological diseases. Topsalysin is in
Phase 2 clinical development for the focal treatment of localized
prostate cancer as well as Phase 3 clinical development for the
treatment of lower urinary tract symptoms of benign prostatic
hyperplasia (BPH). Topsalysin is a highly potent ablative agent
that is selective and targeted in that it is only activated by
enzymatically active PSA which is found in high concentrations in
the transition zone of the prostate and in and around prostate
tumor cells. More than 400 patients have received treatment
with topsalysin, which continues to appear to be safe and well
tolerated. For more information, please visit
www.sophirisbio.com.
Certain statements included in this press release may be
considered forward-looking. Such statements involve known and
unknown risks, uncertainties and other factors that may cause
actual results, performance or achievements to be materially
different from those implied by such statements, and therefore
these statements should not be read as guarantees of future
performance or results. All forward-looking statements are based on
Sophiris' current beliefs as well as assumptions made by and
information currently available to Sophiris and relate to, among
other things, anticipated financial performance, business
prospects, strategies, regulatory developments, market acceptance
and future commitments. Readers are cautioned not to place undue
reliance on these forward-looking statements, which speak only as
of the date of this press release. Due to risks and uncertainties,
including the risks and uncertainties identified by Sophiris in its
public securities filings; actual events may differ materially from
current expectations. Sophiris disclaims any intention or
obligation to update or revise any forward-looking statements,
whether as a result of new information, future events or
otherwise.
Investor Relations and Company Contact:
Peter Slover
Chief Financial Officer
(858) 777-1760
Corporate Communications and Media Contact:
Jason
Spark
Canale Communications
Corporate Communications and Media Contact
(619) 849-6005
jason@canalecomm.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/sophiris-bio-to-present-at-16th-annual-needham-healthcare-conference-300430806.html
SOURCE Sophiris Bio Inc.